Enovix (NASDAQ:ENVX) Updates Q3 2025 Earnings Guidance

Key Points

• Enovix has issued Q3 2025 earnings guidance, projecting an EPS of -0.180 to -0.140 and revenue between $7.5 million and $8.5 million, both above consensus estimates.
• The company approved a share repurchase program amounting to $60 million, signaling confidence in its current stock valuation.
• Several analysts have recently raised their price targets for Enovix, with the average target now set at $18.73, reflecting a generally positive outlook on the stock.

Enovix (NASDAQ:ENVX - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of -0.180--0.140 for the period, compared to the consensus earnings per share estimate of -0.176. The company issued revenue guidance of $7.5 million-$8.5 million, compared to the consensus revenue estimate of $7.3 million.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ENVX. B. Riley reiterated a "buy" rating and set a $17.00 price objective (up from $12.00) on shares of Enovix in a research note on Thursday, July 10th. TD Cowen upgraded Enovix to a "hold" rating and upped their price target for the stock from $7.00 to $15.00 in a research note on Monday, July 7th. Benchmark upped their price target on Enovix from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $12.00 price target (up from $9.00) on shares of Enovix in a research note on Thursday, July 24th. Finally, Cowen restated a "hold" rating on shares of Enovix in a research note on Tuesday, July 8th. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $18.60.

Enovix Price Performance

Shares of ENVX traded down $2.70 during mid-day trading on Friday, hitting $10.70. 24,263,913 shares of the stock were exchanged, compared to its average volume of 10,370,709. The company has a market cap of $2.05 billion, a PE ratio of -12.74 and a beta of 2.11. Enovix has a 52-week low of $5.27 and a 52-week high of $16.49. The firm has a 50-day moving average of $10.99 and a two-hundred day moving average of $9.37. The company has a debt-to-equity ratio of 0.71, a quick ratio of 4.49 and a current ratio of 4.68.

Enovix (NASDAQ:ENVX - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. Enovix had a negative return on equity of 72.83% and a negative net margin of 481.35%. The business had revenue of $7.50 million for the quarter, compared to analysts' expectations of $5.48 million. During the same period in the prior year, the firm earned ($0.14) EPS. The company's revenue for the quarter was up 98.2% on a year-over-year basis. On average, equities analysts predict that Enovix will post -1.01 earnings per share for the current year.

Enovix announced that its board has authorized a stock buyback plan on Wednesday, July 2nd that authorizes the company to buyback $60.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its stock is undervalued.

Institutional Trading of Enovix

Several hedge funds and other institutional investors have recently bought and sold shares of ENVX. Goldman Sachs Group Inc. raised its holdings in Enovix by 65.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company's stock valued at $8,351,000 after buying an additional 449,934 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Enovix by 18.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company's stock valued at $2,628,000 after buying an additional 55,676 shares during the period. Caxton Associates LLP purchased a new stake in Enovix during the 1st quarter valued at $190,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Enovix by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company's stock valued at $722,000 after acquiring an additional 4,780 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in Enovix by 10.4% in the 1st quarter. NewEdge Advisors LLC now owns 26,257 shares of the company's stock valued at $193,000 after acquiring an additional 2,481 shares during the last quarter. Hedge funds and other institutional investors own 50.92% of the company's stock.

Enovix Company Profile

Enovix Corporation designs develops and manufactures silicon-anode lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.